;PMID: 4047115
;source_file_2999.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:48..143] = [t:48..143]
;2)section:[e:147..220] = [t:147..220]
;3)sentence:[e:224..416] = [t:224..416]
;4)sentence:[e:417..655] = [t:417..655]
;5)sentence:[e:656..996] = [t:656..996]
;6)sentence:[e:997..1118] = [t:997..1118]
;7)sentence:[e:1119..1394] = [t:1119..1394]
;8)sentence:[e:1395..1527] = [t:1395..1527]
;9)section:[e:1531..1575] = [t:1531..1575]

;section 0 Span:0..42
;N Engl J Med.  1985 Oct 31;313(18):1111-6.
(SEC
  (FRAG (NN:[0..1] N) (NNP:[2..6] Engl) (NNP:[7..8] J) (NNP:[9..12] Med)
        (.:[12..13] .) (CD:[15..19] 1985) (NNP:[20..23] Oct) (CD:[24..26] 31)
        (::[26..27] ;) (CD:[27..30] 313) (-LRB-:[30..31] -LRB-) (CD:[31..33] 18)
        (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..41] 1111-6)
        (.:[41..42] .)))

;sentence 1 Span:48..143
;Association of multiple copies of the N-myc oncogene with rapid progression
;of  neuroblastomas.
;[63..78]:variation-type:"multiple copies"
;[86..91]:gene-rna:"N-myc"
;[128..142]:malignancy-type:"neuroblastomas"
(SENT
  (NP-HLN
    (NP (NN:[48..59] Association))
    (PP (IN:[60..62] of)
      (NP
        (NP (JJ:[63..71] multiple) (NNS:[72..78] copies))
        (PP (IN:[79..81] of)
          (NP (DT:[82..85] the) (NN:[86..91] N-myc) (NN:[92..100] oncogene)))))
    (PP (IN:[101..105] with)
      (NP
        (NP (JJ:[106..111] rapid) (NN:[112..123] progression))
        (PP (IN:[124..126] of)
          (NP (NNS:[128..142] neuroblastomas)))))
    (.:[142..143] .)))

;section 2 Span:147..220
;Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D.
(SEC
  (FRAG (NNP:[147..153] Seeger) (NNP:[154..156] RC) (,:[156..157] ,)
        (NNP:[158..165] Brodeur) (NNP:[166..168] GM) (,:[168..169] ,)
        (NNP:[170..176] Sather) (NNP:[177..178] H) (,:[178..179] ,)
        (NNP:[180..186] Dalton) (NNP:[187..188] A) (,:[188..189] ,)
        (NNP:[190..196] Siegel) (NNP:[197..199] SE) (,:[199..200] ,)
        (NNP:[201..205] Wong) (NNP:[206..208] KY) (,:[208..209] ,)
        (NNP:[210..217] Hammond) (NNP:[218..219] D) (.:[219..220] .)))

;sentence 3 Span:224..416
;Eighty-nine patients with untreated primary neuroblastomas were studied to 
;determine the relation between the number of copies of the N-myc oncogene and
; survival without disease progression.
;[260..267]:malignancy-clinical-stage:"primary"
;[268..282]:malignancy-type:"neuroblastomas"
;[359..364]:gene-rna:"N-myc"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[224..235] Eighty-nine) (NNS:[236..244] patients))
      (PP (IN:[245..249] with)
        (NP (JJ:[250..259] untreated) (JJ:[260..267] primary)
            (NNS:[268..282] neuroblastomas))))
    (VP (VBD:[283..287] were)
      (VP (VBN:[288..295] studied)
        (NP-1 (-NONE-:[295..295] *))
        (S-PRP
          (NP-SBJ (-NONE-:[295..295] *))
          (VP (TO:[296..298] to)
            (VP (VB:[300..309] determine)
              (NP
                (NP (DT:[310..313] the) (NN:[314..322] relation))
                (PP (IN:[323..330] between)
                  (NP
                    (NP
                      (NP (DT:[331..334] the) (NN:[335..341] number))
                      (PP (IN:[342..344] of)
                        (NP
                          (NP (NNS:[345..351] copies))
                          (PP (IN:[352..354] of)
                            (NP (DT:[355..358] the) (NN:[359..364] N-myc)
                                (NN:[365..373] oncogene))))))
                    (CC:[374..377] and)
                    (NP
                      (NP (NN:[379..387] survival))
                      (PP (IN:[388..395] without)
                        (NP (NN:[396..403] disease) (NN:[404..415] progression))))))))))))
    (.:[415..416] .)))

;sentence 4 Span:417..655
;Genomic amplification (3 to 300 copies) of  N-myc was detected in 2 of 16
;tumors in Stage II, 13 of 20 in Stage III, and 19  of 40 in Stage IV; in
;contrast, 8 Stage I and 5 Stage IV-S tumors all had 1 copy  of the gene (P
;less than 0.01).
;[425..438]:variation-type:"amplification"
;[461..466]:gene-rna:"N-myc"
;[501..509]:malignancy-clinical-stage:"Stage II"
;[523..532]:malignancy-clinical-stage:"Stage III"
;[551..559]:malignancy-clinical-stage:"Stage IV"
;[576..583]:malignancy-clinical-stage:"Stage I"
;[590..600]:malignancy-clinical-stage:"Stage IV-S"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (JJ:[417..424] Genomic) (NN:[425..438] amplification)
          (PRN (-LRB-:[439..440] -LRB-)
            (NP
              (QP (CD:[440..441] 3) (TO:[442..444] to) (CD:[445..448] 300))
              (NNS:[449..455] copies))
            (-RRB-:[455..456] -RRB-)))
        (PP (IN:[457..459] of)
          (NP (NN:[461..466] N-myc))))
      (VP (VBD:[467..470] was)
        (VP (VBN:[471..479] detected)
          (NP-1 (-NONE-:[479..479] *))
          (PP-LOC (IN:[480..482] in)
            (NP
              (NP
                (NP (CD:[483..484] 2))
                (PP (IN:[485..487] of)
                  (NP
                    (NP (CD:[488..490] 16) (NNS:[491..497] tumors))
                    (PP (IN:[498..500] in)
                      (NP (NN:[501..506] Stage) (CD:[507..509] II))))))
              (,:[509..510] ,)
              (NP
                (NP (CD:[511..513] 13))
                (PP (IN:[514..516] of)
                  (NP
                    (NP (CD:[517..519] 20))
                    (PP (IN:[520..522] in)
                      (NP (NN:[523..528] Stage) (CD:[529..532] III))))))
              (,:[532..533] ,) (CC:[534..537] and)
              (NP
                (NP (CD:[538..540] 19))
                (PP (IN:[542..544] of)
                  (NP
                    (NP (CD:[545..547] 40))
                    (PP (IN:[548..550] in)
                      (NP (NN:[551..556] Stage) (CD:[557..559] IV)))))))))))
    (::[559..560] ;)
    (S
      (PP (IN:[561..563] in)
        (NP (NN:[564..572] contrast)))
      (,:[572..573] ,)
      (NP-SBJ
        (NP (CD:[574..575] 8)
          (NML (NN:[576..581] Stage) (CD:[582..583] I))
          (NML-2 (-NONE-:[583..583] *P*)))
        (CC:[584..587] and)
        (NP (CD:[588..589] 5)
          (NML (NN:[590..595] Stage) (NN:[596..600] IV-S))
          (NML-2 (NNS:[601..607] tumors))))
      (DT:[608..611] all)
      (VP (VBD:[612..615] had)
        (NP
          (NP (CD:[616..617] 1) (NN:[618..622] copy))
          (PP (IN:[624..626] of)
            (NP (DT:[627..630] the) (NN:[631..635] gene))))
        (PRN (-LRB-:[636..637] -LRB-)
          (S
            (NP-SBJ (NN:[637..638] P))
            (ADJP-PRD
              (ADJP (JJR:[639..643] less))
              (PP (IN:[644..648] than)
                (NP (CD:[649..653] 0.01)))))
          (-RRB-:[653..654] -RRB-))))
    (.:[654..655] .)))

;sentence 5 Span:656..996
;Analysis of progression-free survival in all  patients revealed that
;amplification of N-myc was associated with the worst  prognosis (P less than
;0.0001); the estimated progression-free survival at 18  months was 70 per
;cent, 30 per cent, and 5 per cent for patients whose tumors  had 1, 3 to 10,
;or more than 10 N-myc copies, respectively.
;[725..738]:variation-type:"amplification"
;[742..747]:gene-rna:"N-myc"
;[969..974]:gene-rna:"N-myc"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[656..664] Analysis))
        (PP (IN:[665..667] of)
          (NP
            (ADJP (NN:[668..679] progression) (HYPH:[679..680] -)
                  (JJ:[680..684] free))
            (NN:[685..693] survival)))
        (PP (IN:[694..696] in)
          (NP (DT:[697..700] all) (NNS:[702..710] patients))))
      (VP (VBD:[711..719] revealed)
        (SBAR (IN:[720..724] that)
          (S
            (NP-SBJ-1
              (NP (NN:[725..738] amplification))
              (PP (IN:[739..741] of)
                (NP (NN:[742..747] N-myc))))
            (VP (VBD:[748..751] was)
              (VP (VBN:[752..762] associated)
                (NP-1 (-NONE-:[762..762] *))
                (PP-CLR (IN:[763..767] with)
                  (NP (DT:[768..771] the) (JJS:[772..777] worst)
                      (NN:[779..788] prognosis)))
                (PRN (-LRB-:[789..790] -LRB-)
                  (S
                    (NP-SBJ (NN:[790..791] P))
                    (ADJP-PRD
                      (ADJP (JJR:[792..796] less))
                      (PP (IN:[797..801] than)
                        (NP (CD:[802..808] 0.0001)))))
                  (-RRB-:[808..809] -RRB-))))))))
    (::[809..810] ;)
    (S
      (NP-SBJ
        (NP (DT:[811..814] the) (VBN:[815..824] estimated)
          (ADJP (NN:[825..836] progression) (HYPH:[836..837] -)
                (JJ:[837..841] free))
          (NN:[842..850] survival))
        (PP (IN:[851..853] at)
          (NP (CD:[854..856] 18) (NNS:[858..864] months))))
      (VP (VBD:[865..868] was)
        (NP-PRD
          (NP
            (NP (CD:[869..871] 70))
            (PP (IN:[872..875] per)
              (NP (NN:[876..880] cent))))
          (,:[880..881] ,)
          (NP
            (NP (CD:[882..884] 30))
            (PP (IN:[885..888] per)
              (NP (NN:[889..893] cent))))
          (,:[893..894] ,) (CC:[895..898] and)
          (NP
            (NP (CD:[899..900] 5))
            (PP (IN:[901..904] per)
              (NP (NN:[905..909] cent)))))
        (PP (IN:[910..913] for)
          (NP
            (NP (NNS:[914..922] patients))
            (SBAR
              (WHNP-2 (WP$:[923..928] whose) (NNS:[929..935] tumors))
              (S
                (NP-SBJ-2 (-NONE-:[935..935] *T*))
                (VP (VBD:[937..940] had)
                  (NP
                    (NP (CD:[941..942] 1)
                      (NML-3 (-NONE-:[942..942] *P*)))
                    (,:[942..943] ,)
                    (NP
                      (QP (CD:[944..945] 3) (TO:[946..948] to)
                          (CD:[949..951] 10))
                      (NML-3 (-NONE-:[951..951] *P*)))
                    (,:[951..952] ,) (CC:[953..955] or)
                    (NP
                      (QP (JJR:[956..960] more) (IN:[961..965] than)
                          (CD:[966..968] 10))
                      (NML-3 (NN:[969..974] N-myc) (NNS:[975..981] copies))))
                  (,:[981..982] ,)
                  (ADVP (RB:[983..995] respectively)))))))))
    (.:[995..996] .)))

;sentence 6 Span:997..1118
;Of 16 Stage II  tumors, 2 with amplification metastasized, whereas only 1 of
;14 without  amplification did so (P = 0.03).
;[1003..1011]:malignancy-clinical-stage:"Stage II"
;[1028..1041]:variation-type:"amplification"
;[1086..1099]:variation-type:"amplification"
(SENT
  (S
    (PP (IN:[997..999] Of)
      (NP (CD:[1000..1002] 16)
        (NML (NN:[1003..1008] Stage) (CD:[1009..1011] II))
        (NNS:[1013..1019] tumors)))
    (,:[1019..1020] ,)
    (NP-SBJ
      (NP (CD:[1021..1022] 2))
      (PP (IN:[1023..1027] with)
        (NP (NN:[1028..1041] amplification))))
    (VP (VBD:[1042..1054] metastasized) (,:[1054..1055] ,)
      (SBAR-ADV (IN:[1056..1063] whereas)
        (S
          (NP-SBJ
            (NP
              (ADVP (RB:[1064..1068] only))
              (CD:[1069..1070] 1))
            (PP (IN:[1071..1073] of)
              (NP
                (NP (CD:[1074..1076] 14))
                (PP (IN:[1077..1084] without)
                  (NP (NN:[1086..1099] amplification))))))
          (VP (VBD:[1100..1103] did)
            (ADVP (RB:[1104..1106] so))
            (PRN (-LRB-:[1107..1108] -LRB-)
              (S
                (NP-SBJ (NN:[1108..1109] P))
                (VP (SYM:[1110..1111] =)
                  (NP (CD:[1112..1116] 0.03))))
              (-RRB-:[1116..1117] -RRB-))))))
    (.:[1117..1118] .)))

;sentence 7 Span:1119..1394
;Stage IV tumors with amplification progressed  most rapidly: nine months
;after diagnosis the estimated progression-free  survival was 61 per cent, 47
;per cent, and 0 per cent in patients whose tumors  had 1, 3 to 10, or more
;than 10 copies, respectively (P less than 0.0001).
;[1119..1127]:malignancy-clinical-stage:"Stage IV"
;[1140..1153]:variation-type:"amplification"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (NN:[1119..1124] Stage) (CD:[1125..1127] IV))
        (NNS:[1128..1134] tumors))
      (PP (IN:[1135..1139] with)
        (NP (NN:[1140..1153] amplification))))
    (VP (VBD:[1154..1164] progressed)
      (ADVP (RBS:[1166..1170] most) (RB:[1171..1178] rapidly))
      (::[1178..1179] :)
      (S-ADV
        (PP-TMP
          (NP (CD:[1180..1184] nine) (NNS:[1185..1191] months))
          (IN:[1192..1197] after)
          (NP (NN:[1198..1207] diagnosis)))
        (NP-SBJ (DT:[1208..1211] the) (VBN:[1212..1221] estimated)
          (ADJP (NN:[1222..1233] progression) (HYPH:[1233..1234] -)
                (JJ:[1234..1238] free))
          (NN:[1240..1248] survival))
        (VP (VBD:[1249..1252] was)
          (NP-PRD
            (NP
              (NP (CD:[1253..1255] 61))
              (PP (IN:[1256..1259] per)
                (NP (NN:[1260..1264] cent))))
            (,:[1264..1265] ,)
            (NP
              (NP (CD:[1266..1268] 47))
              (PP (IN:[1269..1272] per)
                (NP (NN:[1273..1277] cent))))
            (,:[1277..1278] ,) (CC:[1279..1282] and)
            (NP
              (NP (CD:[1283..1284] 0))
              (PP (IN:[1285..1288] per)
                (NP (NN:[1289..1293] cent)))))
          (PP-LOC (IN:[1294..1296] in)
            (NP
              (NP (NNS:[1297..1305] patients))
              (SBAR
                (WHNP-1 (WP$:[1306..1311] whose) (NNS:[1312..1318] tumors))
                (S
                  (NP-SBJ-1 (-NONE-:[1318..1318] *T*))
                  (VP (VBD:[1320..1323] had)
                    (NP
                      (NP (CD:[1324..1325] 1)
                        (NML-2 (-NONE-:[1325..1325] *P*)))
                      (,:[1325..1326] ,)
                      (NP
                        (QP (CD:[1327..1328] 3) (TO:[1329..1331] to)
                            (CD:[1332..1334] 10))
                        (NML-2 (-NONE-:[1334..1334] *P*)))
                      (,:[1334..1335] ,) (CC:[1336..1338] or)
                      (NP
                        (QP (JJR:[1339..1343] more) (IN:[1344..1348] than)
                            (CD:[1349..1351] 10))
                        (NML-2 (NNS:[1352..1358] copies))))
                    (,:[1358..1359] ,)
                    (ADVP (RB:[1360..1372] respectively)
                      (PRN (-LRB-:[1373..1374] -LRB-)
                        (S
                          (NP-SBJ (NN:[1374..1375] P))
                          (ADJP-PRD
                            (ADJP (JJR:[1376..1380] less))
                            (PP (IN:[1381..1385] than)
                              (NP (CD:[1386..1392] 0.0001)))))
                        (-RRB-:[1392..1393] -RRB-)))))))))))
    (.:[1393..1394] .)))

;sentence 8 Span:1395..1527
;These  results suggest that genomic amplification of N-myc may have a key
;role in  determining the aggressiveness of neuroblastomas.
;[1431..1444]:variation-type:"amplification"
;[1448..1453]:gene-rna:"N-myc"
;[1512..1526]:malignancy-type:"neuroblastomas"
(SENT
  (S
    (NP-SBJ (DT:[1395..1400] These) (NNS:[1402..1409] results))
    (VP (VBP:[1410..1417] suggest)
      (SBAR (IN:[1418..1422] that)
        (S
          (NP-SBJ
            (NP (JJ:[1423..1430] genomic) (NN:[1431..1444] amplification))
            (PP (IN:[1445..1447] of)
              (NP (NN:[1448..1453] N-myc))))
          (VP (MD:[1454..1457] may)
            (VP (VB:[1458..1462] have)
              (NP (DT:[1463..1464] a) (JJ:[1465..1468] key)
                  (NN:[1469..1473] role))
              (PP (IN:[1474..1476] in)
                (S-NOM
                  (NP-SBJ (-NONE-:[1476..1476] *))
                  (VP (VBG:[1478..1489] determining)
                    (NP
                      (NP (DT:[1490..1493] the) (NN:[1494..1508] aggressiveness))
                      (PP (IN:[1509..1511] of)
                        (NP (NNS:[1512..1526] neuroblastomas))))))))))))
    (.:[1526..1527] .)))

;section 9 Span:1531..1575
;PMID: 4047115 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1531..1535] PMID) (::[1535..1536] :) (CD:[1537..1544] 4047115)
        (NN:[1545..1546] -LSB-) (NNP:[1546..1552] PubMed) (::[1553..1554] -)
        (NN:[1555..1562] indexed) (IN:[1563..1566] for)
        (NNP:[1567..1574] MEDLINE) (-RRB-:[1574..1575] -RSB-)))
